Aesculap has launched M.blue valve in the US in partnership with The Christoph Miethke (MIETHKE) for treating hydrocephalus-related headaches.
Hydrocephalus is a condition caused by excessive accumulation of cerebrospinal fluid in the brain. The disorder causes chronic headaches, vomiting, abnormal head enlargement and may even lead to death.
The M.blue valve is designed for various forms of hydrocephalus. The device can also be customised to provide optimal therapy to patients.
Aesculap president Chuck DiNardo said: “We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions.
“With our strong partnership with MIETHKE comes an impactful collaborative effort to bring better hydrocephalus solutions to patients such as the new M.blue valve.”
Featuring an adjustable gravitational unit and a fixed differential pressure unit, the M.blue valve operates in a position-dependent manner.
In combination, the two units ensure automatic adjustment of the opening pressure based on the patient’s body position and reduce the risk of over-drainage complications.
According to the company, the M.blue valve is the smallest adjustable gravitational valve currently available in the US market.
MIETHKE founder and CEO Christoph Miethke said: “The patient is our priority and we will continue to invest in research and development to create better solutions.
“Our focus on hydrocephalus valves creates expertise and openness to future developments that allow us to serve in a way that will improve the lives that we touch.”
It is estimated that more than one million people in the US live with hydrocephalus condition, according to the Hydrocephalus Association.